#1 Clinical Trials Search in Europe

Midostaurin

Midostaurin, also known as PKC412, is an investigational drug being studied in clinical trials for various blood cancers, particularly acute myeloid leukemia (AML) and systemic mastocytosis. This article summarizes key findings from several clinical trials examining the safety and efficacy of midostaurin in different patient populations and treatment settings.

Table of Contents

What is Midostaurin?

Midostaurin is a medication used in the treatment of certain blood cancers and rare blood disorders. It is also known by its brand name Rydapt and was previously referred to as PKC412 or CGP41251 during its development[1]. Midostaurin belongs to a class of drugs called tyrosine kinase inhibitors, which work by blocking specific proteins that contribute to cancer growth[2].

What Conditions Does Midostaurin Treat?

Midostaurin is primarily used to treat the following conditions:

  • Acute Myeloid Leukemia (AML): A type of blood cancer that affects the bone marrow and blood. Midostaurin is specifically used for AML patients who have a genetic mutation called FLT3 (FMS-like tyrosine kinase 3)[3].
  • Systemic Mastocytosis: A rare condition where too many mast cells (a type of white blood cell) accumulate in the body. Midostaurin is used in various forms of this disease, including:
    • Aggressive Systemic Mastocytosis (ASM)
    • Systemic Mastocytosis with Associated Hematologic Neoplasm (SM-AHN)
    • Mast Cell Leukemia (MCL)
    • Indolent Systemic Mastocytosis (ISM)[2]

How Does Midostaurin Work?

Midostaurin is a multi-kinase inhibitor, which means it blocks several enzymes (kinases) that are important for cancer cell growth and survival. Specifically, it targets:

  • FLT3: A protein often mutated in AML, leading to uncontrolled cell growth
  • KIT (c-KIT): A protein that, when mutated, can cause systemic mastocytosis
  • Other kinases involved in cell signaling and growth[1]

By inhibiting these proteins, midostaurin can help slow or stop the growth of cancer cells and abnormal mast cells[2].

How is Midostaurin Administered?

Midostaurin is typically taken orally in the form of capsules. The dosage and schedule can vary depending on the condition being treated and individual patient factors. Some common administration patterns include:

  • For AML: 50 mg (two 25 mg capsules) twice daily, often in combination with chemotherapy[4]
  • For systemic mastocytosis: 100 mg (four 25 mg capsules) twice daily[1]

It’s important to take midostaurin exactly as prescribed by your doctor. The medication is usually taken with food and water[5].

Clinical Trials and Research

Midostaurin has been the subject of numerous clinical trials to evaluate its effectiveness and safety. Some key findings include:

  • Improved survival rates in AML patients with FLT3 mutations when combined with standard chemotherapy[4]
  • Significant symptom improvement and reduction of mast cell burden in patients with systemic mastocytosis[2]
  • Potential effectiveness in treating pediatric patients with relapsed or refractory leukemia[6]

Ongoing research is exploring the use of midostaurin in other conditions and in combination with other treatments[7].

Potential Side Effects

Like all medications, midostaurin can cause side effects. Common side effects may include:

  • Nausea and vomiting
  • Diarrhea
  • Headache
  • Fatigue
  • Increased risk of infections

More serious side effects can occur, particularly in patients with compromised liver function[5]. It’s important to discuss all potential side effects with your healthcare provider.

Important Considerations for Patients

If you’re considering or currently taking midostaurin, keep these points in mind:

  • Inform your doctor about all medications and supplements you’re taking, as midostaurin can interact with other drugs.
  • Regular blood tests may be necessary to monitor your response to the treatment.
  • If you have liver problems, your doctor may need to adjust your dosage[5].
  • Midostaurin may be used as part of a treatment plan that includes other medications or procedures, such as stem cell transplantation[4].
  • Always follow your doctor’s instructions regarding dosage and administration.

Midostaurin represents an important advance in the treatment of certain blood cancers and disorders. While it can be highly effective for some patients, it’s crucial to work closely with your healthcare team to determine if it’s the right treatment for you and to manage any potential side effects.

Aspect Details
Primary Indications Acute Myeloid Leukemia (AML) with FLT3 mutations, Aggressive Systemic Mastocytosis (ASM), Mast Cell Leukemia (MCL)
Mechanism of Action Broad-spectrum protein kinase inhibitor, targeting FLT3, c-KIT, and other enzymes
Administration Oral capsules, typically 50 mg twice daily
Trial Phases Phase I, II, and expanded access programs
Key Outcome Measures Overall survival, event-free survival, response rates, minimal residual disease (MRD) status
Safety Monitoring Adverse events, particularly in combination with chemotherapy and post-transplant
Special Populations Newly diagnosed AML, relapsed/refractory AML, post-transplant maintenance
Combination Therapies With standard induction and consolidation chemotherapy in AML

FAQ

  • What is midostaurin and how does it work? Midostaurin is a broad-spectrum protein kinase inhibitor that targets several enzymes involved in cancer cell growth, particularly FLT3 and c-KIT. It works by blocking these enzymes, potentially slowing or stopping the growth of cancer cells.
  • What types of cancer is midostaurin being studied for? Midostaurin is primarily being studied for acute myeloid leukemia (AML), particularly in patients with FLT3 mutations. It's also being investigated for aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL).
  • How is midostaurin administered in clinical trials? In most trials, midostaurin is given orally as capsules, typically 50 mg twice daily. The dosing schedule may vary depending on the specific trial and treatment phase.
  • What are some potential side effects of midostaurin? While specific side effects vary by trial, common adverse events monitored include gastrointestinal issues, fatigue, and changes in blood cell counts. The trials closely monitor for any serious adverse events.
  • Is midostaurin approved for use outside of clinical trials? Midostaurin (brand name Rydapt) has been approved for use in some countries for newly diagnosed FLT3-mutated AML in combination with chemotherapy. However, its use in other settings or as a single agent is still being investigated in clinical trials.

Ongoing Clinical Trials on Midostaurin

  • Study on Midostaurin and Gemtuzumab Ozogamicin for Adults with Acute Myeloid Leukemia

    Recruiting

    1 1 1
    Investigated drugs:
    Germany

  • Study on Personalized Treatment for Acute Myeloid Leukemia Using Cladribine, Daunorubicin, Cytarabine, and Drug Combinations for Specific Patient Groups

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

  • Study on Early Treatment Intensification for Acute Myeloid Leukemia with FLT3 Mutation Using Cytarabine, Midostaurin, and Daunorubicin Hydrochloride for Patients with Low Chemosensitivity

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

    Not recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Finland France Germany Ireland +5

  • Study on Midostaurin and Chemotherapy for Children with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

    Not recruiting

    1 1 1
    Investigated drugs:
    Austria Czechia Germany Italy Poland Slovenia

  • Study on Midostaurin and Decitabine for Adults with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Who Are Unfit for Intensive Treatment

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium The Netherlands

Glossary

  • Acute Myeloid Leukemia (AML): A type of blood cancer that starts in the bone marrow and quickly moves into the blood, affecting the production of normal blood cells.
  • FLT3: FMS-like tyrosine kinase 3, a protein involved in the growth of blood cells. Mutations in the FLT3 gene can lead to increased growth of leukemia cells.
  • Systemic Mastocytosis: A rare condition where mast cells accumulate in various tissues, potentially causing organ damage. It can be indolent (slow-growing) or aggressive.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Minimal Residual Disease (MRD): Small numbers of cancer cells that remain in the body during or after treatment, often detectable only by highly sensitive tests.
  • Allogeneic Stem Cell Transplantation: A procedure where a patient receives blood-forming stem cells from a genetically similar, but not identical, donor to replace diseased bone marrow.
  • Tyrosine Kinase Inhibitor (TKI): A type of targeted therapy that blocks specific enzymes called tyrosine kinases, which are involved in cancer cell growth and survival.
  • Graft-versus-Host Disease (GvHD): A complication that can occur after allogeneic stem cell transplantation, where the donor's immune cells attack the recipient's tissues.

References

  1. https://clinicaltrials.gov/study/NCT00233454
  2. https://clinicaltrials.gov/study/NCT01920204
  3. https://clinicaltrials.gov/study/NCT02624570
  4. https://clinicaltrials.gov/study/NCT02723435
  5. https://clinicaltrials.gov/study/NCT01429337
  6. https://clinicaltrials.gov/study/NCT00866281
  7. https://clinicaltrials.gov/study/NCT03951961